Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00973141 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 467
- Enrollment target
NCT00973141: Clinical Trial Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00973141 is a Phase 2 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 467 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (251% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00973141, a Phase 2 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 467 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and effectiveness of different doses of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe knee or hip pain in patients with a diagnosis of osteoarthritis.
Interventions
- DRUG Placebo
- DRUG JNJ-42160443
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2009-09-16 |
| Est. Completion | 2011-06-30 |
| Phase | Phase 2 |
Why NCT00973141 stopped before completion
NCT00973141 is an interventional study that assigns participants to a tested intervention. The registered 467 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (251% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00973141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00973141 about?
NCT00973141 is a clinical study titled "A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain". The purpose of this study is to compare the safety and effectiveness of different doses of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe knee or hip pain in patients with a diagnosis of osteoarthritis.
What is the current status of trial NCT00973141?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 467 participants. The study started on 2009-09-16. Estimated completion is 2011-06-30.
What interventions are being tested in trial NCT00973141?
The interventions under investigation include: Placebo (DRUG), JNJ-42160443 (DRUG).
Who is sponsoring clinical trial NCT00973141?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00973141's enrollment target sits among peer trials
467 80th of 2000 higher than 1,921 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06456554 · 467 participants · NA
Acellular Dermal Matrix Investigation in Breast Reconstruction
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI